Astellas Pharma (OTCMKTS:ALPMY) Rating Lowered to Hold at Zacks Research

Astellas Pharma (OTCMKTS:ALPMY) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Separately, Jefferies Financial Group upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

Astellas Pharma Stock Performance

Shares of ALPMY opened at $13.09 on Wednesday. The company has a market cap of $23.69 billion, a price-to-earnings ratio of 12.19 and a beta of 0.07. The business’s fifty day simple moving average is $13.51 and its two-hundred day simple moving average is $14.64. Astellas Pharma has a 12 month low of $9.91 and a 12 month high of $17.35. The company has a current ratio of 1.17, a quick ratio of 0.90 and a debt-to-equity ratio of 0.17.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings results on Monday, April 27th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.14. Astellas Pharma had a return on equity of 23.54% and a net margin of 13.66%.The firm had revenue of $3.38 billion during the quarter, compared to analysts’ expectations of $3.28 billion. Research analysts anticipate that Astellas Pharma will post 1.25 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).